No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial

Blood Pressure

Volumn 25, Issue 2, 2016, Pages 83-92

  Kjeldsen, Sverre E ^a,b   Berge, Eivind ^a   Bangalore, Sripal ^c   Messerli, Franz H ^d   Mancia, Giuseppe ^e   Holzhauer, Björn ^f   Hua, Tsushung A ^f   Zappe, Dion ^f   Zanchetti, Alberto ^g   Weber, Michael A ^h   Julius, Stevo ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Blood pressure lowering treatment; cardiovascular morbidity; cardiovascular mortality; clinical trial; hypertension

Indexed keywords

AMLODIPINE; CHOLESTEROL; HYDROCHLOROTHIAZIDE; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GENDER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DIASTOLE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; SYSTOLE; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CORONARY ARTERY DISEASE; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; SYSTOLE; TREATMENT OUTCOME; VALSARTAN;

EID: 84958122230     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2015.1106750     Document Type: Article

References (19)

1. Tanna MS, Bangalore S. Antihypertensive therapy and the J-curve: fact or fiction? Curr Hypertens Rep. 2015;17:6-14.
2. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC practice guidelines for the management of arterial hypertension by the ESH-ESC. Blood Press. 2014;23:3-16.
3. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary heart disease. A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435-470.
4. Kjeldsen SE, Julius S, Brunner H, et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. 2001;10:83-91.
5. Julius S, Kjeldsen SE, Weber M, et al. Cardiac events, stroke and mortality in high-risk hypertensives treated with valsartan or amlodipine: main outcomes of the VALUE Trial. Lancet. 2004;363:2022-2031.
6. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
7. Messerli FH, Mancia G, Weber MA, et al. Low blood pressure is associated with increased cardiovascular morbidity (J-shaped curve) in treated hypertensive patients with increased cardiovascular risk: the VALUE randomized trial. JACC. 2009;53(Suppl A):A46.
8. Messerli FH, Mancia G, Conti CR, et al. "Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?" Ann Intern Med. 2006;144:884-893.
9. Bangalore S, Messerli FH, Wun CC, et al., for the Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-2908.
10. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels - overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296-2304.
11. Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11:532-546.
12. National Heart, Lung, and Blood Institute. Landmark NIH study shows intensive blood pressure management may save lives. Available from: http://www.nhlbi.nih.gov/news/press-releases/2015/landmark-nih-study-shows-intensive-blood-pressure-management-may-save-lives webpage accessed 11 September 2015.
13. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited again - SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 2015;25:1-3.
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
15. Cushman WC, Evans GW, Byington RP, et al. for the ACCORD Study Group. Effect of intensive blood pressure control in type-2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
16. Benavente OR, Coffey CS, Conwit R, Hart RG, et al. For the SPS3 Study Group, blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-515.
17. Aksnes TA, Kjeldsen SE, Rostrup M, et al. Effect of new-onset diabetes mellitus on cardiac mortality and morbidity in the VALUE trial population. Hypertension. 2007;50:467-473.
18. Sandset EC, Krarup L-H, Berge E, et al. Heart rate as a predictor of recurrent stroke in a hypertensive population with previous stroke or transient ischemic attacks. J Stroke Cerebrovasc Dis. 2014;23:2814-2818.
19. Zanchetti A, Liu L, Mancia G, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens. 2014;32:1888-1897.